261 related articles for article (PubMed ID: 10606626)
1. Suppression of ongoing experimental myasthenia by oral treatment with an acetylcholine receptor recombinant fragment.
Im SH; Barchan D; Fuchs S; Souroujon MC
J Clin Invest; 1999 Dec; 104(12):1723-30. PubMed ID: 10606626
[TBL] [Abstract][Full Text] [Related]
2. Suppression of experimental myasthenia gravis by a B-cell epitope-free recombinant acetylcholine receptor.
Yi HJ; Chae CS; So JS; Tzartos SJ; Souroujon MC; Fuchs S; Im SH
Mol Immunol; 2008 Nov; 46(1):192-201. PubMed ID: 18799218
[TBL] [Abstract][Full Text] [Related]
3. Oral administration of acetylcholine receptor: effects on experimental myasthenia gravis.
Okumura S; McIntosh K; Drachman DB
Ann Neurol; 1994 Nov; 36(5):704-13. PubMed ID: 7979216
[TBL] [Abstract][Full Text] [Related]
4. Role of tolerogen conformation in induction of oral tolerance in experimental autoimmune myasthenia gravis.
Im SH; Barchan D; Souroujon MC; Fuchs S
J Immunol; 2000 Oct; 165(7):3599-605. PubMed ID: 11034361
[TBL] [Abstract][Full Text] [Related]
5. T cell reactivity to acetylcholine receptor in rats orally tolerized against experimental autoimmune myasthenia gravis.
Wang ZY; Qiao J; Melms A; Link H
Cell Immunol; 1993 Dec; 152(2):394-404. PubMed ID: 8258147
[TBL] [Abstract][Full Text] [Related]
6. Mechanism of nasal tolerance induced by a recombinant fragment of acetylcholine receptor for treatment of experimental myasthenia gravis.
Im SH; Barchan D; Fuchs S; Souroujon MC
J Neuroimmunol; 2000 Nov; 111(1-2):161-8. PubMed ID: 11063834
[TBL] [Abstract][Full Text] [Related]
7. Immunosuppression of rat myasthenia gravis by oral administration of a syngeneic acetylcholine receptor fragment.
Maiti PK; Feferman T; Im SH; Souroujon MC; Fuchs S
J Neuroimmunol; 2004 Jul; 152(1-2):112-20. PubMed ID: 15223243
[TBL] [Abstract][Full Text] [Related]
8. Specificity of the T cell immune response to acetylcholine receptor in experimental autoimmune myasthenia gravis. Response to subunits and synthetic peptides.
Fujii Y; Lindstrom J
J Immunol; 1988 Mar; 140(6):1830-7. PubMed ID: 2450133
[TBL] [Abstract][Full Text] [Related]
9. On the initial trigger of myasthenia gravis and suppression of the disease by antibodies against the MHC peptide region involved in the presentation of a pathogenic T-cell epitope.
Atassi MZ; Oshima M; Deitiker P
Crit Rev Immunol; 2001; 21(1-3):1-27. PubMed ID: 11642597
[TBL] [Abstract][Full Text] [Related]
10. Mechanisms of nasal tolerance induction in experimental autoimmune myasthenia gravis: identification of regulatory cells.
Shi FD; Li H; Wang H; Bai X; van der Meide PH; Link H; Ljunggren HG
J Immunol; 1999 May; 162(10):5757-63. PubMed ID: 10229808
[TBL] [Abstract][Full Text] [Related]
11. Experimental autoimmune myasthenia gravis may occur in the context of a polarized Th1- or Th2-type immune response in rats.
Saoudi A; Bernard I; Hoedemaekers A; Cautain B; Martinez K; Druet P; De Baets M; Guéry JC
J Immunol; 1999 Jun; 162(12):7189-97. PubMed ID: 10358165
[TBL] [Abstract][Full Text] [Related]
12. Animal models of myasthenia gravis.
Christadoss P; Poussin M; Deng C
Clin Immunol; 2000 Feb; 94(2):75-87. PubMed ID: 10637092
[TBL] [Abstract][Full Text] [Related]
13. Blockade of CD40 ligand suppresses chronic experimental myasthenia gravis by down-regulation of Th1 differentiation and up-regulation of CTLA-4.
Im SH; Barchan D; Maiti PK; Fuchs S; Souroujon MC
J Immunol; 2001 Jun; 166(11):6893-8. PubMed ID: 11359850
[TBL] [Abstract][Full Text] [Related]
14. Protective potential of experimental autoimmune myasthenia gravis in Lewis rats by IL-10-modified dendritic cells.
Duan RS; Adikari SB; Huang YM; Link H; Xiao BG
Neurobiol Dis; 2004 Jul; 16(2):461-7. PubMed ID: 15193302
[TBL] [Abstract][Full Text] [Related]
15. Role for interferon-gamma in rat strains with different susceptibility to experimental autoimmune myasthenia gravis.
Wang HB; Shi FD; Li H; van der Meide PH; Ljunggren HG; Link H
Clin Immunol; 2000 May; 95(2):156-62. PubMed ID: 10779409
[TBL] [Abstract][Full Text] [Related]
16. Suppression of myasthenia gravis by antigen-specific mucosal tolerance and modulation of cytokines and costimulatory factors.
Souroujon MC; Maiti PK; Feferman T; Im SH; Raveh L; Fuchs S
Ann N Y Acad Sci; 2003 Sep; 998():533-6. PubMed ID: 14592924
[TBL] [Abstract][Full Text] [Related]
17. The limitation of IL-10-exposed dendritic cells in the treatment of experimental autoimmune myasthenia gravis and myasthenia gravis.
Xiao BG; Duan RS; Zhu WH; Lu CZ
Cell Immunol; 2006 Jun; 241(2):95-101. PubMed ID: 17005165
[TBL] [Abstract][Full Text] [Related]
18. FK506 prevents induction of rat experimental autoimmune myasthenia gravis.
Yoshikawa H; Iwasa K; Satoh K; Takamori M
J Autoimmun; 1997 Feb; 10(1):11-6. PubMed ID: 9080295
[TBL] [Abstract][Full Text] [Related]
19. Combined short-term immunotherapy for experimental autoimmune myasthenia gravis.
Pestronk A; Drachman DB; Teoh R; Adams RN
Ann Neurol; 1983 Aug; 14(2):235-41. PubMed ID: 6354071
[TBL] [Abstract][Full Text] [Related]
20. Modulation of the anti-acetylcholine receptor response and experimental autoimmune myasthenia gravis by recombinant fragments of the acetylcholine receptor.
Barchan D; Asher O; Tzartos SJ; Fuchs S; Souroujon MC
Eur J Immunol; 1998 Feb; 28(2):616-24. PubMed ID: 9521072
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
